(Reuters) - Diagnostics products maker Neoprobe Corp said U.S. health regulators have indicated that data from a late-stage trial of its radioactive tracing agent would support filing for marketing ...
A new radioactive tracer for positron emission tomography (PET) myocardial perfusion imaging will soon be available in the United States, and it’s expected to facilitate substantial growth in such ...
Says FDA indicated that trial data to support NDA Expects Lymphoseek approval in 2011 March 11 (Reuters) - Diagnostics products maker Neoprobe Corp said U.S. health regulators have indicated that data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results